Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Equity Ratio (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Equity Ratio for 8 consecutive years, with 0.94 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 17.1% to 0.94 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.94, a 17.1% increase, with the full-year FY2024 number at 0.75, down 6.06% from a year prior.
  • Equity Ratio was 0.94 for Q3 2025 at Whitehawk Therapeutics, down from 0.95 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.95 in Q2 2025 to a low of 0.52 in Q2 2021.
  • A 5-year average of 0.72 and a median of 0.86 in 2023 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 317.47% in 2021; the steepest drop was 34.18% in 2021.
  • Whitehawk Therapeutics' Equity Ratio stood at 0.86 in 2021, then fell by 0.48% to 0.86 in 2022, then fell by 7.59% to 0.79 in 2023, then fell by 6.06% to 0.75 in 2024, then rose by 26.1% to 0.94 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Equity Ratio are 0.94 (Q3 2025), 0.95 (Q2 2025), and 0.95 (Q1 2025).